# JK-1201I Compared with Topotecan in Patients with Relapsed Extensive Stage Small Cell Lung Cancer

> **NCT06581380** · PHASE3 · NOT_YET_RECRUITING · sponsor: **JenKem Technology Co., Ltd.** · enrollment: 394 (estimated)

## Conditions studied

- Small Cell Lung Cancer

## Interventions

- **DRUG:** JK-1201I
- **DRUG:** Topotecan

## Key facts

- **NCT ID:** NCT06581380
- **Lead sponsor:** JenKem Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-09-16
- **Primary completion:** 2027-11-16
- **Final completion:** 2028-04-16
- **Target enrollment:** 394 (ESTIMATED)
- **Last updated:** 2024-09-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06581380

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06581380, "JK-1201I Compared with Topotecan in Patients with Relapsed Extensive Stage Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06581380. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*